Astellas Pharma (OTCMKTS:ALPMY) Stock Price Up 4.9% – Should You Buy?

Astellas Pharma Inc. (OTCMKTS:ALPMY) was up 4.9% on Friday. The stock traded as high as $15.0525 and last traded at $15.0525. 85,696 shares changed hands during trading, a decline of 44% from the average daily volume of 152,989 shares. The stock had previously closed at $14.35.

Analyst Upgrades and Downgrades

Separately, Zacks Research downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

Astellas Pharma Stock Performance

The company has a fifty day moving average price of $14.77 and a two-hundred day moving average price of $14.45. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.20 and a quick ratio of 0.93. The company has a market capitalization of $27.65 billion, a P/E ratio of 11.63 and a beta of 0.08.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Japan-based pharmaceutical company that researches, develops, manufactures and commercializes prescription medicines for patients worldwide. Its portfolio focuses on areas of significant unmet medical need, including oncology, immunology, urology, ophthalmology, neuroscience and medical conditions related to genetic regulation.

The company’s products include XTANDI (enzalutamide) for certain prostate cancers, XOSPATA (gilteritinib) for acute myeloid leukemia, PADCEV (enfortumab vedotin-ejfv) for certain urothelial cancers, and PROGRAF (tacrolimus), an immunosuppressant used primarily to help prevent organ rejection following transplantation.